Bihua Chen - 16 Jun 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BBOT
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:55:36 UTC
Prior SEC filing: 28 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Bihua Chen

Key filing fact

Bihua Chen filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 18 Jun 2026.

Key facts

This page summarizes Bihua Chen's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 16:55.

Change

Previous filing in this sequence was filed on 28 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001599214 Primary reporting owner

Chen Bihua

Relationship: Director, 10%+ Owner
Address: C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON ST, 50TH FLOOR, BOSTON
Signature: /s/ Bihua Chen
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +31,675
Change %
Price: $0.000000^*
Shares after: 31,675
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,675
Exercise price: $7.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.